{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Child+Safety",
    "query": {
      "condition": "Child Safety"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 1356,
    "total_pages": 136,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Child+Safety&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-22T07:37:02.284Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00355615",
      "title": "PLUTO: Pediatric Lipid-redUction Trial of rOsuvastatin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Familial Hypercholesterolemia"
      ],
      "interventions": [
        {
          "name": "Rosuvastatin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "10 Years to 17 Years"
      },
      "enrollment_count": 173,
      "start_date": "2006-07",
      "completion_date": "2008-07",
      "has_results": true,
      "last_update_posted_date": "2011-08-31",
      "last_synced_at": "2026-07-22T07:37:02.284Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Hyde Park, New York • Cincinnati, Ohio + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Hyde Park",
          "state": "New York"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Wexford",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00355615"
    },
    {
      "nct_id": "NCT00743652",
      "title": "Study Evaluating the Impact of the 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Alaskan Native Children.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pneumococcal Disease",
        "13-valent Pneumococcal Vaccine"
      ],
      "interventions": [
        {
          "name": "13-valent Pneumococcal Conjugate Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "42 Days",
        "maximum_age": "5 Years",
        "sex": "ALL",
        "summary": "42 Days to 5 Years"
      },
      "enrollment_count": 373,
      "start_date": "2009-01",
      "completion_date": "2010-09",
      "has_results": true,
      "last_update_posted_date": "2012-03-15",
      "last_synced_at": "2026-07-22T07:37:02.284Z",
      "location_count": 21,
      "location_summary": "Akiak, Alaska • Bethel, Alaska • Chefornak, Alaska + 18 more",
      "locations": [
        {
          "city": "Akiak",
          "state": "Alaska"
        },
        {
          "city": "Bethel",
          "state": "Alaska"
        },
        {
          "city": "Chefornak",
          "state": "Alaska"
        },
        {
          "city": "Chevak",
          "state": "Alaska"
        },
        {
          "city": "Eek",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00743652"
    },
    {
      "nct_id": "NCT00179855",
      "title": "Extracorporeal Photopheresis for Acute Graft Versus Host Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Graft Versus Host Disease",
        "Cancer",
        "Stem Cell Transplantation"
      ],
      "interventions": [
        {
          "name": "Extracorporeal Photopheresis",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Ann & Robert H Lurie Children's Hospital of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "Up to 30 Years"
      },
      "enrollment_count": 10,
      "start_date": "2003-07",
      "completion_date": "2010-08",
      "has_results": false,
      "last_update_posted_date": "2025-02-12",
      "last_synced_at": "2026-07-22T07:37:02.284Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00179855"
    },
    {
      "nct_id": "NCT02096952",
      "title": "Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Attention-deficit/Hyperactivity Disorder",
        "Autism Spectrum Disorder"
      ],
      "interventions": [
        {
          "name": "Methylphenidate extended-release liquid formulation",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 15,
      "start_date": "2014-05",
      "completion_date": "2018-01",
      "has_results": true,
      "last_update_posted_date": "2024-07-01",
      "last_synced_at": "2026-07-22T07:37:02.284Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02096952"
    },
    {
      "nct_id": "NCT00849693",
      "title": "A Study in the Treatment of Children and Adolescents With Major Depressive Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Major Depressive Disorder"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "fluoxetine",
          "type": "DRUG"
        },
        {
          "name": "duloxetine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "7 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "7 Years to 17 Years"
      },
      "enrollment_count": 463,
      "start_date": "2009-03",
      "completion_date": "2011-09",
      "has_results": true,
      "last_update_posted_date": "2012-04-19",
      "last_synced_at": "2026-07-22T07:37:02.284Z",
      "location_count": 44,
      "location_summary": "Birmingham, Alabama • Dothan, Alabama • Little Rock, Arkansas + 41 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Carson",
          "state": "California"
        },
        {
          "city": "Escondido",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00849693"
    },
    {
      "nct_id": "NCT04520685",
      "title": "CASCADE: CAnnabidiol Study in Children With Autism Spectrum DisordEr",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Autism Spectrum Disorder"
      ],
      "interventions": [
        {
          "name": "Oral cannabidiol 100mg/mL",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "5 Years to 17 Years"
      },
      "enrollment_count": 86,
      "start_date": "2021-12-15",
      "completion_date": "2024-12-31",
      "has_results": false,
      "last_update_posted_date": "2024-05-08",
      "last_synced_at": "2026-07-22T07:37:02.284Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04520685"
    },
    {
      "nct_id": "NCT04816643",
      "title": "Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "SARS-CoV-2 Infection, COVID-19"
      ],
      "interventions": [
        {
          "name": "Biological/Vaccine: BNT162b2 10mcg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BNT162b2 20mcg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BNT162b2 30mcg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Biological/Vaccine: BNT162b2 3mcg",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "BioNTech SE",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "15 Years",
        "sex": "ALL",
        "summary": "6 Months to 15 Years"
      },
      "enrollment_count": 11837,
      "start_date": "2021-03-24",
      "completion_date": "2023-12-08",
      "has_results": true,
      "last_update_posted_date": "2026-05-28",
      "last_synced_at": "2026-07-22T07:37:02.284Z",
      "location_count": 90,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 67 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Madera",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04816643"
    },
    {
      "nct_id": "NCT05721235",
      "title": "A Safety/Tolerability and PK Study With Azstarys® in Children With ADHD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Attention Deficit/Hyperactivity Disorder"
      ],
      "interventions": [
        {
          "name": "Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Corium, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "5 Years",
        "sex": "ALL",
        "summary": "4 Years to 5 Years"
      },
      "enrollment_count": 123,
      "start_date": "2023-06-02",
      "completion_date": "2025-07-31",
      "has_results": true,
      "last_update_posted_date": "2026-05-08",
      "last_synced_at": "2026-07-22T07:37:02.284Z",
      "location_count": 20,
      "location_summary": "Little Rock, Arkansas • Anaheim, California • Centennial, Colorado + 17 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Centennial",
          "state": "Colorado"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Lakeland",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05721235"
    },
    {
      "nct_id": "NCT00002015",
      "title": "An Open Label Evaluation of the Safety and Pharmacokinetics of Ganciclovir in Children",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cytomegalovirus Retinitis",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Ganciclovir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Roche Global Development",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Months",
        "maximum_age": "12 Years",
        "sex": "ALL",
        "summary": "3 Months to 12 Years"
      },
      "enrollment_count": 20,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2005-06-24",
      "last_synced_at": "2026-07-22T07:37:02.284Z",
      "location_count": 8,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 3 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002015"
    },
    {
      "nct_id": "NCT03760458",
      "title": "The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC) Dispersible Tablets",
          "type": "DRUG"
        },
        {
          "name": "Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC) Immediate Release Tablets (Immediate release)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "11 Years",
        "sex": "ALL",
        "summary": "Up to 11 Years"
      },
      "enrollment_count": 57,
      "start_date": "2020-09-09",
      "completion_date": "2022-05-31",
      "has_results": true,
      "last_update_posted_date": "2023-06-27",
      "last_synced_at": "2026-07-22T07:37:02.284Z",
      "location_count": 5,
      "location_summary": "Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03760458"
    }
  ]
}